Literature DB >> 7665572

Quantitative polymerase chain reaction of lysyl oxidase mRNA in malignantly transformed human cell lines demonstrates that their low lysyl oxidase activity is due to low quantities of its mRNA and low levels of transcription of the respective gene.

E R Hämäläinen1, R Kemppainen, H Kuivaniemi, G Tromp, A Vaheri, T Pihlajaniemi, K I Kivirikko.   

Abstract

Lysyl oxidase (EC 1.4.3.13), an extracellular copper amino oxidase, initiates the cross-linking of collagens and elastin by catalyzing oxidative deamination of the epsilon-amino group in certain lysine and hydroxylysine residues. We developed here a polymerase chain reaction (PCR) method for the quantification of lysyl oxidase mRNA in which a synthetic RNA is used as an internal standard for coamplification with the targeted mRNA. The amount of lysyl oxidase mRNA when studied by Northern blot analysis and the number of lysyl oxidase mRNA molecules when determined by the quantitative PCR method were found to be markedly low in various malignantly transformed cell lines relative to control cell lines, quantitative PCR indicating values of about 2-10% of those in the controls. No difference was found in the number of beta-actin mRNA molecules between the transformed cells and the controls. Nuclear runoff experiments indicated that most if not all of the decrease in the number of lysyl oxidase mRNA molecules can be explained by diminished transcription of the respective gene.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7665572     DOI: 10.1074/jbc.270.37.21590

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

Review 1.  Human copper-dependent amine oxidases.

Authors:  Joel Finney; Hee-Jung Moon; Trey Ronnebaum; Mason Lantz; Minae Mure
Journal:  Arch Biochem Biophys       Date:  2014-01-06       Impact factor: 4.013

2.  Epigenetic inhibition of lysyl oxidase transcription after transformation by ras oncogene.

Authors:  S Contente; K Kenyon; P Sriraman; S Subramanyan; R M Friedman
Journal:  Mol Cell Biochem       Date:  1999-04       Impact factor: 3.396

3.  The Ras signaling inhibitor LOX-PP interacts with Hsp70 and c-Raf to reduce Erk activation and transformed phenotype of breast cancer cells.

Authors:  Seiichi Sato; Philip C Trackman; Joni M Mäki; Johanna Myllyharju; Kathrin H Kirsch; Gail E Sonenshein
Journal:  Mol Cell Biol       Date:  2011-05-02       Impact factor: 4.272

4.  The lysyl oxidase propeptide interacts with the receptor-type protein tyrosine phosphatase kappa and inhibits β-catenin transcriptional activity in lung cancer cells.

Authors:  Nuria Sánchez-Morgan; Kathrin H Kirsch; Philip C Trackman; Gail E Sonenshein
Journal:  Mol Cell Biol       Date:  2011-06-20       Impact factor: 4.272

Review 5.  Lysyl oxidase: a potential target for cancer therapy.

Authors:  V M Berlin Grace; C Guruvayoorappan
Journal:  Inflammopharmacology       Date:  2010-11-24       Impact factor: 4.473

6.  Lysyl oxidase, extracellular matrix remodeling and cancer metastasis.

Authors:  Qian Xiao; Gaoxiang Ge
Journal:  Cancer Microenviron       Date:  2012-04-13

7.  Lysyl oxidase inhibits ras-mediated transformation by preventing activation of NF-kappa B.

Authors:  Sébastien Jeay; Stefania Pianetti; Herbert M Kagan; Gail E Sonenshein
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

8.  Prognostic implications of carboxyl-terminus of Hsc70 interacting protein and lysyl-oxidase expression in human breast cancer.

Authors:  Neill Patani; Wen Jiang; Robert Newbold; Kefah Mokbel
Journal:  J Carcinog       Date:  2010-11-12

9.  Lysyl oxidase propeptide inhibits prostate cancer cell growth by mechanisms that target FGF-2-cell binding and signaling.

Authors:  A H Palamakumbura; S R Vora; M A Nugent; K H Kirsch; G E Sonenshein; P C Trackman
Journal:  Oncogene       Date:  2009-07-13       Impact factor: 9.867

10.  A loss-of-function polymorphism in the propeptide domain of the LOX gene and breast cancer.

Authors:  Chengyin Min; Ziyang Yu; Kathrin H Kirsch; Yingshe Zhao; Siddharth R Vora; Philip C Trackman; Douglas B Spicer; Lynn Rosenberg; Julie R Palmer; Gail E Sonenshein
Journal:  Cancer Res       Date:  2009-08-04       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.